The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 1st 2024
Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.
Novel PD-1/PD-L1 Inhibitor Combo Promotes Antitumor Activity in Urothelial Carcinoma
September 18th 2020The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.
Combination Biomarker Is Predictive of Response to Immunotherapy in Metastatic Urothelial Carcinoma
August 13th 2020The combination of ARID1A mutations and the immune signaling protein CXCL13 proved to be predictive of clinical response and prolonged survival after treatment with checkpoint inhibitors in patients with metastatic urothelial carcinoma.
FDA Grants Breakthrough Designation to Frontline Enfortumab Vedotin/Pembrolizumab in Bladder Cancer
February 20th 2020The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv and pembrolizumab as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.
Frontline Enfortumab Vedotin Plus Pembrolizumab Shows Encouraging Data in Advanced Urothelial Cancer
February 11th 2020Enfortumab vedotin-ejfv combined with pembrolizumab led to an objective response rate of 73% in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy.
New Chapter Opens in Bladder Cancer Treatment
For years, the treatment landscape for bladder cancer was defined by lackluster consistency: There were no advances. However, the drought ended with the introduction of immune checkpoint blockade, according to Charles G. Drake, MD, PhD.
Adjuvant Atezolizumab Misses DFS Endpoint in Muscle-Invasive Bladder Cancer
January 24th 2020Adjuvant treatment with atezolizumab did not significantly improve disease-free survival compared with observation in patients with muscle-invasive bladder cancer, missing the primary endpoint of the phase III IMvigor010 trial.
FDA Approves Pembrolizumab for High-Risk NMIBC
January 9th 2020The FDA has approved pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Avelumab Improves OS as Frontline Maintenance in Urothelial Carcinoma
January 6th 2020Frontline maintenance therapy with avelumab plus best supportive care demonstrated a statistically significant improvement in overall survival compared with best supportive care alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
FDA Panel Supports Pembrolizumab for High-Risk NMIBC
December 18th 2019The FDA’s Oncologic Drugs Advisory Committee voted in support of approving pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
FDA Grants Pembrolizumab Priority Review for High-Risk NMIBC
December 2nd 2019The FDA has granted a priority review designation to pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Dr. Powles on Design and Findings of the BISCAY Trial in Platinum-Refractory Urothelial Cancer
October 31st 2019Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.
Dr. Zhang on the IMvigor130 Trial in Metastatic Urothelial Cancer
October 12th 2019Tian Zhang, MD, discusses data from the randomized phase III IMvigor130 trial, which compared the safety and efficacy of atezolizumab in combination with platinum-based chemotherapy, atezolizumab monotherapy, and chemotherapy alone, in the frontline treatment of patients with metastatic urothelial cancer.